Bharat Parenterals’ arm signs deal with two Global Complex Generic marketing companies

13 Mar 2024 Evaluate

Bharat Parenterals’ subsidiary Innoxel Lifesciences has signed a deal to out license seven complex molecules including two, 505(b) 2 products with two Global Complex Generic marketing companies. According to agreement, Innoxel Lifesciences will receive cumulative milestone payments of Rs 31 crore over the period of next three years (Rs 10.3 crore every year). Primary countries for Marketing will be United States and some of the European countries.

Innoxel Lifesciences has developed total twenty-two complex generic molecules, including seven 505(b) 2. Additional sixteen molecules are in pipeline and likely to be developed over the next two years. Innoxel Lifesciences has a state-of-the-art manufacturing facility with SKID based technology in Vadodara to manufacture these drugs. On successful filing and approval of these molecules, company will manufacture drugs on contract manufacturing basis and will also receive Profit Share income after commercialisation in the future.

Innoxel Lifesciences was incorporated in the year 2021 with the vision of developing and manufacturing of highly complex generic molecules, including 505(b) 2 for the regulated markets, mainly the United States and select Western European countries.

Bharat Parenterals is engaged in to the business of the Pharmaceuticals & Drugs.

Bharat Parenterals Share Price

1268.15 46.10 (3.77%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×